



LEGISLATIVE FISCAL OFFICE
Fiscal Note

Fiscal Note On: **HB 1154** HLS 26RS 2660
 Bill Text Version: **ENROLLED**
 Opp. Chamb. Action:
 Proposed Amd.:
 Sub. Bill For.:

Date: May 26, 2026	1:02 PM	Author: GLORIOSO
Dept./Agy.: Louisiana Department of Insurance		Analyst: Anthony Shamis
Subject: Prohibits PA requirements for certain generic medications		

INSURANCE EN NO IMPACT GF EX See Note Page 1 of 1
 Prohibits prior authorizations requirements for certain generic medications prescribed by qualified physicians

Proposed law adds definitions for the terms "board-certified physician," "commercial insurer," "generic medication," and "prior authorization" to present law. Proposed law provides that the term "commercial insurer" shall not include federal, state, or local governmental health plans. Proposed law prohibits a commercial insurer from requiring prior authorization (PA) for the dispensing or reimbursement of a generic medication that is not an opioid, if the prescription for the medication is issued by a board-certified physician or authorized provider whose specialty certification includes the medical indication for which the drug is prescribed and the wholesale acquisition cost is no more than \$250 per prescription.

Proposed law applies to any new policy, contract, or health coverage plan issued on and after January 1, 2027. Any policy, contract, or health coverage plan contract in effect prior to January 1, 2027, shall convert to conform to the provisions of proposed law no later than January 1, 2028.

EXPENDITURES	2026-27	2027-28	2028-29	2029-30	2030-31	5 -YEAR TOTAL
State Gen. Fd.	\$0	\$0	\$0	\$0	\$0	\$0
Agy. Self-Gen.	\$0	\$0	\$0	\$0	\$0	\$0
Ded./Other	\$0	\$0	\$0	\$0	\$0	\$0
Federal Funds	\$0	\$0	\$0	\$0	\$0	\$0
Local Funds	\$0	\$0	\$0	\$0	\$0	\$0
Annual Total	\$0	\$0	\$0	\$0	\$0	\$0

REVENUES	2026-27	2027-28	2028-29	2029-30	2030-31	5 -YEAR TOTAL
State Gen. Fd.	\$0	\$0	\$0	\$0	\$0	\$0
Agy. Self-Gen.	\$0	\$0	\$0	\$0	\$0	\$0
Ded./Other	\$0	\$0	\$0	\$0	\$0	\$0
Federal Funds	\$0	\$0	\$0	\$0	\$0	\$0
Local Funds	\$0	\$0	\$0	\$0	\$0	\$0
Annual Total	\$0	\$0	\$0	\$0	\$0	\$0

EXPENDITURE EXPLANATION

There is no anticipated direct material effect on governmental expenditures as a result of this measure. Proposed law is not expected to have an expenditure impact on the Louisiana Department of Health (LDH), the Louisiana Department of Insurance (LDI), or the Office of Group Benefits (OGB) associated with prohibiting prior authorization for certain generic medications prescribed by qualified physicians or authorized providers.

REVENUE EXPLANATION

There is no anticipated direct material effect on governmental revenues as a result of this measure.

Senate Dual Referral Rules
 13.5.1 >= \$100,000 Annual Fiscal Cost {S & H}
 13.5.2 >= \$500,000 Annual Tax or Fee Change {S & H}

House
 6.8(F)(1) >= \$100,000 SGF Fiscal Cost {H & S}
 6.8(G) >= \$500,000 Tax or Fee Increase or a Net Fee Decrease {S}

Alan M. Boxberger
 Alan M. Boxberger
 Legislative Fiscal Officer